Table 2. Adverse events, cytokine release syndrome, and neurological toxic effects.
| Total (n=22) no. (%) | InstanCART group (n=7) no. (%) | TraditionCART group (n=15) no. (%) | ||||
| Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | |
| Any adverse event* | 22 (100) | 21 (95) | 7 (100) | 7 (100) | 15 (100) | 14 (93) |
| Cytokine release syndrome | 19 (86) | 0 | 7 (100) | 0 | 12 (80) | 0 |
| Neurological toxic effect | 2 (9) | 0 | 1 (14) | 0 | 1 (7) | 0 |
| Neutropenia | 22 (100) | 20 (91) | 7 (100) | 6 (86) | 15 (100) | 14 (93) |
| Anemia | 22 (100) | 12 (55) | 7 (100) | 2 (29) | 15 (100) | 10 (67) |
| Thrombocytopenia | 22 (100) | 15 (68) | 7 (100) | 6 (86) | 12 (80) | 9 (60) |
| Creatinine increased | 4 (18) | 1 (5) | 0 | 0 | 4 (27) | 1 (7) |
| Hepatic enzymes increased | 12 (55) | 5 (23) | 4 (57) | 3 (43) | 8 (53) | 2 (13) |
| Diarrhea | 6 (27) | 0 | 3 (43) | 0 | 3 (20) | 0 |
| Upper respiratory tract infection | 2 (9) | 0 | 1 (14) | 0 | 3 (20) | 0 |
| Sepsis | 1 (5) | 1 (5) | 0 | 0 | 1 (7) | 1 (7) |
*
Shown are adverse events that occurred during the first 1 month month after CAR-T infusion.
CAR-Tchimeric antigen receptor T cellInstanCARTinstant manufacturing platformTraditionCARTtraditional manufacturing process